The global cardiovascular drug market is anticipated to grow at a considerable CAGR of 1.2% during the forecast period (2021-2027). The technology advancement in healthcare is one of the prime factors affecting and driving the market. According to World Health Organisation (WHO) around 17.9 million people across the globe die due to cardiovascular diseases (CVD) every year. The digital health technology will support in prevention, diagnosis along with proper management of cardiovascular diseases that leads to getting better health outcomes. Additionally, with introduction of biomarkers and new diagnostic tools (cardiac scans) are also supporting in analysing the risk factor and diagnosis in order to give proper and effective treatment to patients.
Browse the full report description of "Global Cardiovascular Drug Market Research By Drug Type (Anti-Clotting Agents, Antihyperlipidemic, Calcium Channel Blockers, Renin-Angiotensin System Blockers and Other), By Disease Type (Arrhythmia, Coronary Artery Disease, Hyperlipidemia, Hypertension and Peripheral Artery Disease), and By Distribution Channel (Hospital Pharmacy, Online Pharmacy and Retail Pharmacy) Forecast Period 2021-2027" at https://www.omrglobal.com/industry-reports/cardiovascular-drug-market
The key players operating in the global cardiovascular drug market had been adopting strategy such as new launches to gain major market share. For instance, in April 2021, F. Hoffmann-La Roche Ltd. had put forward its two biomarkers named high-sensitive cardiac troponin T (cTnT-hs) along with N-terminal pro-brain natriuretic peptide test (NT-proBNP). The cTnT-hs will support clinicians in diagnosis related with heart attack along with managing the cardiovascular diseases as it helps in evaluating the long-term risk of diseases by using Elecsys technology.
Market Coverage
• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered-
o By Drug Type
o By Disease Type
o By Distribution Channel
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Cardiovascular Drug Market - Segmentation
By Drug Type
• Anti-Clotting Agents
• Antihyperlipidemic
• Calcium Channel Blockers
• Renin-Angiotensin System Blockers
• Other
By Disease Type
• Arrhythmia
• Coronary Artery Disease
• Hyperlipidemia
• Hypertension
• Peripheral Artery Disease
By Distribution Channel
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
Global Cardiovascular Drug Market by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/cardiovascular-drug-market